News

Cadent Therapeutics announced that FDA accepted its IND application for SK channel modulator for the treatment of spinocerebellar ataxia

BY      |     January 25, 2020

Cadent Therapeutics, a biopharmaceutical company developing novel treatments for patients with movement and cognitive disorders, announced that FDA accepted its IND application for CAD-1883 for the treatment of spinocerebellar ataxia.

CAD-1883 is a first-in-class selective positive allosteric modulator of SK channels (small conductance, calcium-activated potassium ion channels).

Cadent Therapeutics is now looking forward to initiating Phase 2 randomized trial in order to evaluate the safety and efficacy of CAD-1883.

Read more about Cadent Therapeutics here.


Image by Darko Stojanovic from Pixabay


Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at [email protected]
Alternatively, you can leave your comments on LinkedIn or Twitter.